Bittium Corporation
Inside information

Bittium Corporation’s Subsidiary, Bittium Biosignals Ltd. Starts Change Negotiations in Finland

Bittium Corporation, Stock Exchange Release, May 7, 2025, at 9.00 am (CEST+1)

As part of the measures to improve profitability and develop operations, Bittium Corporation has today decided to start change negotiations in its subsidiary, Bittium Biosignals Ltd., which is operating the Finnish entity of Medical Business Segment. The negotiations concern the whole personnel of Bittium Biosignals Ltd, a total of 102 employees. The planned measures, if implemented, could lead to a termination of employment or lay-offs of a maximum of 20 employees. Change negotiations are initiated for financial and production-related reasons as well as for reasons related to the reorganization of the company’s operations.

Bittium has earlier announced that it plans to renew the Medical Business Segment’s organization, improve the competitiveness of the products, focus the operations further, and grow profitable international business. Through reorganization and sharper operational focus, the company seeks to streamline its cost structure and improve profitability. Bittium also continues to optimize its processes and improve its operational efficiency.

With these measures to improve profitability and strengthen competitiveness, Bittium aims for annual cost savings of approximately EUR 2.0 million. The impact of the cost savings is expected to materialize in full in 2026.

Oulu Finland,
May 7, 2025

Bittium Corporation
Petri Toljamo
CEO
 

Further Information:

Karoliina Malmi
Vice President, Communications & Sustainability
Tel. +358 40 344 2789

Distribution

NASDAQ Helsinki
Main media

Bittium

Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its 40-year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. Bittium also provides healthcare technology products and services for biosignal measuring in the areas of cardiology and neurophysiology. Net sales in 2024 were EUR 85.2 million and operating profit EUR 8.6 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com

Files
Bittium Corporation's Subsidiary, Bittium Biosignals Ltd. Starts Change Negotiations in Finland (wkr0006.pdf)